Details

Autor(en) / Beteiligte

• Pfeiffer, Thomas
• Tzannou, Ifigeneia
• Wu, Mengfen
• Ramos, Carlos
• Sasa, Ghadir
• Martinez, Caridad
• Lulla, Premal
• Krance, Robert A
• Scherer, Lauren
• Ruderfer, Daniel
• Naik, Swati
• Bocchini, Claire
• Fraser, Iain P
• Patel, Badrish
• Ward, Dany
• Wang, Tao
• Heslop, Helen E
• Leen, Ann M
• Omer, Bilal

Titel

Posoleucel, an Allogeneic, Off-the-Shelf Multivirus-Specific T-Cell Therapy, for the Treatment of Refractory Viral Infections in the Post-HCT Setting

Ist Teil von

• Clinical cancer research, 2023-01, Vol.29 (2), p.324-330

Ort / Verlag

United States: American Association for Cancer Research

Erscheinungsjahr

2023

Quelle

Electronic Journals Library

Beschreibungen/Notizen

• Viral infections are a major cause of morbidity and mortality following allogeneic hematopoietic cell transplantation (allo-HCT). In the absence of safe and effective antiviral treatments, virus-specific T cells have emerged as a promising therapeutic option. Posoleucel is a multivirus-specific T-cell therapy for off-the-shelf use against six viral infections that commonly occur in allo-HCT recipients: adenovirus, BK virus (BKV), cytomegalovirus, Epstein-Barr virus, human herpes virus-6, and JC virus. We conducted an open-label, phase II trial to determine the feasibility and safety of posoleucel in allo-HCT recipients infected with one or more of these viruses. Infections were either unresponsive to or patients were unable to tolerate standard antiviral therapies. Fifty-eight adult and pediatric patients were enrolled and treated. Posoleucel was well tolerated, with no cytokine release syndrome or other infusion-related toxicities; two patients (3.4%) developed Grade 2 and one patient (1.7%) Grade 3 GvHD during the trial. The overall response rate 6 weeks after the first posoleucel infusion was 95%, with a median plasma viral load reduction of 97%. Of the 12 patients who had two or more target viral infections identified at study entry, 10 (83%) had a clinical response for all evaluable viruses. Of the 23 patients treated for refractory BKV-associated hemorrhagic cystitis, 74% had resolution of symptoms and macroscopic hematuria by 6 weeks post-infusion. In this open-label trial, treatment of refractory viral infections/disease in allo-HCT recipients with posoleucel was feasible, safe, and effective.